Lab Information

Peter Lakatos (MD)

Investigator
Clinical Research Unit
Department of Medicine (McGill)

Research Profile

 Fundamental: 0%
 Clinical: 50%
 Epidemiology: 0%
 Evaluation: 50%
 This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords

Inflammatory bowel diseases (IBD) • gastroenterology • colitis • Crohn’s disease

Team Members

Name Position

Latest Publications

  1. Wetwittayakhlang, P. & Lakatos, P. L. (2024). Advanced combination therapy: is it the best way to break the therapeutic ceiling?. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241272995.
  2. Abbas, A., Di Fonzo, D. M. P., Wetwittayakhlang, P., Al-Jabri, R., Lakatos, P. L. & Bessissow, T. (2024). Management of ulcerative colitis: where are we at and where are we heading?. Expert review of gastroenterology & hepatology, p. 1-8.
  3. Bacsur, P., Resál, T., Sarlós, P., Iliás, Á., Dalma Sümegi, L., Kata, D., Dávid, A., Farkas, B., Ivány, E., Bálint, A., Bősze, Z., Fábián, A., Bor, R., Szepes, Z., Afif, W., Bessissow, T., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241290636.
  4. Lalani, S., Mathias, H., Heisler, C., Rohatinsky, N., Mirza, R. M., Kits, O., Zelinsky, S., Nguyen, G., Lakatos, P. L., Fowler, S., Rioux, K. & Jones, J. L. (2024). Improving access to inflammatory bowel disease care in Canada: The patient experience. Journal of health services research & policy, p. 13558196241276979.
  5. Angyal, M. M., Janssen, M. F., Lakatos, P. L., Brodszky, V. & Rencz, F. (2024). The added value of the cognition, dining, gastrointestinal problems, sleep and tiredness bolt-on dimensions to the EQ-5D-5L in patients with coeliac disease. The European journal of health economics : HEPAC : health economics in prevention and care.
  6. Shehab, M., De Marco, D., Lakatos, P. L. & Bessissow, T. (2024). The potential for medical therapies to address fistulizing Crohn's disease: a state-of-the-art review. Expert opinion on biological therapy, p. 1-14.
  7. Barkai, L. J., Gonczi, L., Balogh, F., Angyal, D., Farkas, K., Farkas, B., Molnar, T., Szamosi, T., Schafer, E., Golovics, P. A., Juhasz, M., Patai, A., Vincze, A., Sarlos, P., Farkas, A., Dubravcsik, Z., Toth, T. G., Szekely, H., Miheller, P., Lakatos, P. L. & Ilias, A. (2024). Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years. Scientific reports, vol. 14, p. 14909.
  8. Pattarapuntakul, T., Wong, T., Wetwittayakhlang, P., Netinatsunton, N., Keeratichananont, S., Kaewdech, A., Jandee, S., Chamroonkul, N., Sripongpun, P. & Lakatos, P. L. (2024). Efficacy of Vonoprazan vs. Intravenous Proton Pump Inhibitor in Prevention of Re-Bleeding of High-Risk Peptic Ulcers: A Randomized Controlled Pilot Study. Journal of clinical medicine, vol. 13.
  9. Wetwittayakhlang, P., Kotrri, G., Bessissow, T. & Lakatos, P. L. (2024). How close are we to a success stratification tool for improving biological therapy in ulcerative colitis?. Expert opinion on biological therapy, p. 1-9.
  10. Medawar, E., Djinbachian, R., Crainic, I. P., Safih, W., Battat, R., Mccurdy, J., Lakatos, P. L. & von Renteln, D. (2024). Serrated Polyps in Inflammatory Bowel Disease Indicate a Similar Risk of Metachronous Colorectal Neoplasia as in the General Population. Digestive diseases and sciences, vol. 69, p. 2595-2610.
More on PubMed 



See also

Card image
Talat
Bessissow


See profile
Card image
Waqqas
Afif


See profile
Card image
Alain
Bitton


See profile
Card image
Paul
Brassard


See profile
Card image
Jean-Pierre
Routy


See profile
Card image
Bertrand
Lebouché


See profile